INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection

PISCATAWAY, N.J., Oct. 25, 2011 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of its Abbreviated New Drug Application (ANDA) for olanzapine injection (the generic equivalent of Zyprexa® injection).

As the developer of this generic injectable drug, INNOPHARMA entered into an agreement with Sandoz Inc., pursuant to which Sandoz will sell, market and distribute the product in the United States.  

About INNOPHARMA:

INNOPHARMA is a sterile product development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.    

Zyprexa® is a registered trademark of Eli Lilly and Company

SOURCE INNOPHARMA LLC

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.